A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa

Conditions: Healthy Participants; Non-cystic Fibrosis Bronchiectasis
Interventions: Combination Product: Rev-56 for Inhalation; Drug: Placebo: Normal saline
Sponsors: Revagenix, Inc.; National Institute of Allergy and Infectious Diseases (NIAID)
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.